Skip to content
Signal Bureau What’s happening · what the record shows

Astrazeneca

Anglo-Swedish pharma major with a deep oncology and respiratory pipeline.

Coverage of Astrazeneca is holding steady : 2 signals on the latest tracked day, down 33% from its three-week baseline of 3, across 2 domains (down from 3 a week ago). That makes it the #253 most-covered of the 349 concerns we track.

What’s changed

5 of the last 7 tracked days ran above the three-week baseline — a sustained move, not a one-day spike.

What the reporting says

Across 41 tracked stories from 14 outlets, reporting on Astrazeneca most often describes regulatory approvals (5), IPOs or listings (1), military action (1), meetings or visits (1), public statements (1).

It shows up alongside Bristol Myers Squibb (14), Merck (13), FDA (12), Abstract (11), Eli Lilly (8), Immunotherapy (8).

Two steps out: Moderna (through Merck, 13 shared stories on the weaker link); AI (through Merck, 12 shared stories on the weaker link); Cder (through FDA, 12 shared stories on the weaker link); Colorectal Cancer (through FDA, 12 shared stories on the weaker link).

Tracked since Apr 12, with coverage on 24 separate days — concentrated in Preprint and FDA Decisions.

Ask the engine about Astrazeneca + Track Astrazeneca for a daily read
Counts computed from our committed signal record (Jul 12 – Aug 15, 10 tracked days). Informational only — not financial, legal, or investment advice. Prediction-market prices are shown as a signal of what the crowd believes. Terms · Privacy · page rendered Aug 26, 12:26 PM PT